News
Drugmaker Novo Nordisk is once again Europe's largest company by market capitalisation, rising above German software firm SAP ...
Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first ...
Novo Nordisk A/S (NYSE:NVO) is one of the 17 stocks that Jim Cramer commented on. During the episode, Cramer said that he ...
The analyst is thus maintaining a cautious stance on the stock. Novo Nordisk A/S (NYSE:NVO) is a global healthcare company ...
2d
GlobalData on MSNNovo Nordisk ramps up obesity fight, advances amycretin to Phase IIINovo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...
Dilok Klaisataporn Most major stock indexes across the globe ended the week lower, following US-China trade talks and renewed ...
Explore more
Novo Nordisk’s shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe’s ...
3d
GlobalData on MSNNovo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugsDeep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.
Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...
Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, ...
Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...
Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results